In 2011, the development of cationic SLN functionalized with a monoclonal antibody (mAb) directed against the epidermal growth factor receptor (EGFR) represented the first step in antibody-mediated strategies using drug-loaded SLN in cancer therapy. The gene discussed is EGFR; the disease is cancer.